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Allogeneic stem cell transplantation (SCT) enhances coagulation via endothelial perturba-
tion and inflammation. Role of natural anticoagulants in interactions between coagulation
and inflammation as well as in acute graft-versus-host disease (GVHD) are not well known.
The purpose of this study was to define changes in natural anticoagulants over time in asso-
ciation with GVHD.
Patients and methods
This prospective study included 30 patients who received grafts from siblings (n = 19) or
unrelated donors (n = 11). Eight patients developed GVHD. Standard clinical assays were
applied to measure natural anticoagulants, represented by protein C (PC), antithrombin
(AT), protein S (PS), complex of activated PC with its inhibitor (APC-PCI) and by markers of
endothelial activation: Factor VIII coagulant activity (FVIII:C) and soluble thrombomodulin
(s-TM) at 6–8 time points over three months.
Results
Overall, PC, AT and FVIII:C increased in parallel after engraftment. Significant correlations
between PC and FVIII:C (r = 0.64–0.82, p<0.001) and between PC and AT (r = 0.62–0.81,
p<0.05) were observed at each time point. Patients with GVHD had 21% lower PC during
conditioning therapy and 55% lower APC-PCI early after transplantation, as well as 37%
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higher values of s-TM after engraftment. The GVHD group had also increases of PC (24%),
FVIII: C (28%) and AT (16%) three months after transplantation.
Conclusion
The coordinated activation of natural anticoagulants in our longitudinal study indicates the
sustained ability of adaptation to endothelial and inflammatory activation during allogenic
SCT treatment. The suboptimal control of coagulation by natural anticoagulants at early
stage of SCT may contribute to onset of GVHD.
Introduction
Allogeneic SCT is the most efficient, and often the only curative treatment modality in various,
usually malignant hematological disorders. The SCT includes conditioning, graft infusion,
engraftment and recovery. Conditioning therapy is used to eradicate hematological cancers,
but is also mandatory to avoid rejection of the graft. This therapy causes vascular injury [1]
leading to activation of coagulation. Bursts of coagulation and fibrinolysis during conditioning
and at later stages of allogeneic SCT have been previously described [2,3].
Coagulation is controlled by natural anticoagulants such as PC and AT. Thrombin, the key
activator of coagulation pathway, activates PC by binding to endothelial TM. APC aided by
cofactor PS cleaves coagulation cofactors V/Va and VIII/VIIIa slowing down the production
of thrombin. APC activity carries also anti-inflammatory, cytoprotective and anti-apoptotic
properties [4–6]. AT inhibits thrombin and other coagulation factors by binding active site,
and this process is enhanced by endothelial heparan sulphate.
Under physiological conditions, endothelium keeps its anticoagulant state. During damage,
activated endothelium releases s-TM with the local function to control activation of PC.
Though deficiencies and changes of natural anticoagulants have been reported in patients fol-
lowing autologous and allogeneic SCT [7–12], the contribution of this regulatory system to
clinical outcome of SCT is still poorly understood.
Graft-versus-host disease (GVHD), a major complication of SCT, is caused by immune
reaction of donor T cells towards patient’s organs. Acute GVHD usually occurs before, and
chronic GVHD after around 3 months following transplantation. The early endothelial dam-
age occurring during conditioning regimen contributes to pathogenesis of GVHD [13,14].
Endothelial cells, activated during conditioning contribute to propagation of coagulation
and inflammation. Pro-inflammatory cytokines [15–17] are important for perpetuated inflam-
mation and endothelial damage [1,18,19]. Cytokine-stimulated endothelial cells express tissue
factor, which initiates and amplifies blood coagulation interacting with inflammation. Endo-
thelial switch from an anticoagulant to procoagulant state associates with loss of glycocalicin
and initiation of thrombin and fibrin generation. Fibrin in turns recruits both platelets and
more inflammatory cells, which perpetuating the damage. Therefore, monitoring the evolution
of natural anticoagulant responses together with endothelial damage over time after SCT may
help to define more factors that contribute to aGVHD.
Our previous allogeneic SCT study was focused on coagulation and fibrinolysis. We found
that development of acute GVHD associated with increase of thrombin generation and
decrease of fibrinolysis at early stages of the treatment [3]. In the present study, we report lon-
gitudinal analyses of natural anticoagulants: AT, PC and its cofactor PS, APC-PCI complex, as
well as markers of endothelial activation: FVIII: C and s-TM. We focus on the associations
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between temporal changes of natural anticoagulants and development of GVHD, noting the
limitations of the study size and confounders, such as donor type and infections.
Patients and methods
Patients
Thirty patients undergoing myeloablative allogeneic SCT for a hematological malignancy took
part in this prospective study [3]. The study was approved by the Ethics Committee of the Hel-
sinki University Hospital, and a written informed consent was obtained from each patient.
Laboratory monitoring lasted for 3 months and clinical monitoring for the median of 40
months. 19 patients received transplants from HLA-identical siblings and 11 patients from
matched unrelated donors. Stem cells in 19 cases were harvested from bone marrow and in 11
cases from peripheral blood. The myeloablative conditioning regimen consisted of Cyclophos-
phamide 60 mg/kg once daily i.v. on days -6 and -5 and of total body irradiation (12.0 Gy) in
six fractions (lungs 10 Gy) on days -4 to 0 in all patients. The graft was infused on the day 0.
Cyclosporine and a short course of Methotrexate was given as GVHD prophylaxis. If the
donor was unrelated, 2 mg/kg/day of antithymocyte globulin (ATG; Thymoglobuline1; Sang-
stat, Lyon, France) was administrated on days -3 to -1. Patients receiving grafts from siblings
received methylprednisone (MP) as GVHD prophylaxis from the day +eight, as described
[20]. Acute GVHD was assessed according to published criteria [21], and treated with MP
2–10 mg/kg/day divided into 4 i.v. doses upon appearance [3].
Blood collection and plasma samples analyses
Blood samples were collected before (d -10), and during (d-2) conditioning therapy, early after
transplantation (d+10), after engraftment (d +24), at d+38, d +52 and at the end of the study
(d+90). Blood was collected in the morning, always before possible red cell and platelet trans-
fusions. Samples for coagulation assays were obtained in 109 mM (3.2%) trisodium citrate
from antecubital veins using brief stasis only. After immediate transfer to laboratory, plasma
was isolated by centrifugation for 10 min at 2000 g at 22˚C. Plasma aliquots were stored at
-70˚C if not tested immediately. Blood for APC-PCI assay was collected in special vacuum
tubes (Biopool Stabilyte™, Trinity Biotech, Bray, Ireland) to inhibit the complex formation in
vitro and platelet activation [22]. Blood collected in these tubes were centrifuged for 30 min at
1800 g at 4˚C.
FVIII: C, PC and AT activities and free PS antigen were measured in the Helsinki Univer-
sity Hospital Laboratory using routine procedures: coagulometry (Siemens Healthcare AB)—
FVIII:C; chromogenic assays—AT [(Berichrom1Anthithrombin III(A)] and PC (Beri-
chrom1Protein C), both from Siemens, Marburg, Germany; and automated latex ligand
immunoassay for PS (Instrumentation Laboratory, Lexington, MA, USA). The reference val-
ues were as follow: FVIII: C 52–148%, PC 74–141%, AT 84–108%, PS 66–150% (men) and 50–
137% (women).
Antigen and activity of soluble TM (s-TM-Ag and s-TM-Act) were measured in Stabilyte
plasma using an in-house method [23], with the detection limit 0.03 SEq mL-1 (+3 SD for the
blank sample). In healthy individuals s-TM-Ag ranged 3.5–8.3 SEq mL-1 (men; n = 50) and
3.2–7.2 SEq mL-1 (women; n = 50) and s-TM-Act 2.1–5.7 SEq mL-1 (men) and 3.2–7.2 SEq
mL-1 (women). The intra- and inter-assay coefficients of variation were<8% and<15%,
respectively [22].
APC-PCI complex was measured using the immunochemical sandwich method [22]. The
levels of APC-PCI in healthy individuals ranges between 0.07 and 0.26 μg L-1 with median
equal 0.13 μg L-1 (n = 80). The within-run coefficient of variation (CV %) was 4.8% at 0.15 μg
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L-1 and 3.2% at 0.40 μg L-1, while the between-run CV % was 7.1% at 0.15 and 5.8% at 0.40 μg
L-1 (n = 38).
Statistical methods
Distribution of each variable was tested and an appropriate statistical approach was chosen.
Changes in variables were evaluated with Friedman’s and Dunn’s multiple comparison tests.
Analysis of variance (ANOVA) with repeated measures, the Mann Whitney and t-tests were
used for group comparisons. Correlations were evaluated using Spearman’s rank correlation
coefficients. Two-tailed P-values < 0.05 were considered statistically significant. Statistical cal-
culations were performed using the SPSS for Windows version 15.0 (SPSS, Chicago, IL, USA).
Results
Temporal changes of endothelial activation markers and natural
anticoagulants before and after allogeneic stem cells transplantation
As a marker of acute phase and endothelial activation the von Willebrand factor-bound FVIII
(FVIII: C) was increasing after transplantation (d +10) until engraftment (d+24) and stayed
elevated until the end of study (Fig 1A).
The s-TM antigen (s-TM Ag) which also manifests endothelial activation heightened in
association with the engraftment. The activity of s-TM (s-TM Act) also increased after engraft-
ment (d+24) and both remained up regulated but within range of normal references. After
engraftment, s-TM antigen and activity were positively correlated (p< 0.05). The correlation
coefficients between s-TM Ag and s-TM Act varied from 0.43 to 0.58. The natural anticoagu-
lants PC and AT responded to changes of FVIII: C; the median values of both PC and AT fol-
lowed the pattern of FVIII: C course (Fig 1A, 1D and 1E). After engraftment, both PC and AT
increased approximately 50% and stayed elevated until the end of the study. The five-fold
inter-individual variability of PC and FVIII: C was observed (Fig 1A and 1D). The PS, a cofac-
tor of PC, decreased to low normal values during conditioning, but kept increasing up to the
time point d +38 (Fig 1F). PC, AT and FVIII: C showed significant correlations throughout
the study (Table 1).
APC-PCI complex changes over time
APC-PCI is a sensitive marker of natural anticoagulant system responding to thrombin gener-
ation. The concentration of circulating APC-PCI increased during the conditioning therapy
and remained elevated (Fig 2).
In a previous study [3] of the same group of patients, we measured release of F1+2, a prod-
uct of prothrombin cleavage indicating thrombin generation. We combined the APC-PCI and
the F1+2 values to define a ratio F1+2/APC-PCI, which had the highest values (>3) at the day
d+10 (data not shown).
Onset of GVHD and temporal changes of natural anticoagulants in
allogeneic SCT
The patients were divided into two groups: without acute GVHD (n = 22) and with GVHD
(n = 8). Four GVHD patients were recipients of grafts from unrelated donors (4/11 = 36%).
The aGVHD in this group occurred between 11 and 68 days after transplantation (median 13
days). The four GVHD patients who obtained grafts from siblings showed the first GVHD
symptoms later, between 44–75 days (median 44 days). The seven endothelial and coagulation
variables were tested for associations with GVHD at all time points. Fig 3 presents comparisons
Allogeneic stem cell transplantation and natural anticoagulants
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Fig 1. Longitudinal changes of endothelial activation markers and natural anticoagulants in allogenic
SCT/graft infusion. Endothelial markers: (A) Factor VIII with coagulant activity (FVIII:C); (B) soluble
thrombomodulin antigen (s-TM Ag); (C) soluble thrombomodulin activity (s-TM Act) are shown at 6–7 time
points during allogenic SCT treatment. Activities of natural anticoagulants: (D) protein C; (E) antithrombin; and
(F) protein S were measured at 7–8 time points. Data points represent median values and error bars—25th
and 75th percentiles; comparisons were with baseline values. The horizontal line depicts lower and upper
normal reference limits; d = transplantation /graft infusion day; * = p < 0.05; ** = p < 0.001.
https://doi.org/10.1371/journal.pone.0190007.g001
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between the groups with and without GVHD. Four variables had at least one time point show-
ing significant differences between the groups. These were: FVIII:C, s-TM Ag, PC and AT. In
the GVHD group, PC had significantly lower values at early time points d-2 and d+10, s-TM
Ag was higher at d+24 and d+38, FVIII:C and PC at d+90, and AT at d+90.
Differences between a group with acute GVHD (aGVHD+, N = 8) and without acute
GVHD (aGVHD-, N = 22), are depicted for (A) Factor VIII (B) s-TM endothelial antigen
(C) protein C activity and (D) anthithrombin. Data on panels A and B d are presented as
median values and error bars as the 25th and 75th percentiles; and on panels C and D as mean
values with error bars representing standard errors. d = transplantation day;  = p < 0.05;
 = p < 0.01The significant increase of endothelial activation markers in the GVHD group
was observed for s-TM Ag at 24 and 38 days and for FVIII:C at 90 days after transplantation
(Fig 3A and 3B). The decrease of natural anticoagulant PC occurred at early time points, d-2
and d+10, but clearly elevated at the d+90 day. (Fig 3C). Again, a significant increase in s-
TM Ag level occurred at d+90 in the GVHD group (Fig 3D).
Discussion
The aim of this study was to define a role of natural anticoagulants in the adaptation to
immune milieu during allogenic SCT. We have previously reported the activation of the coag-
ulation system, manifested by thrombin generation and release of prothrombin fragment 1.2
(known as F1+2), during the conditioning therapy and later stages of allogeneic SCT [3]. In
Table 1. Correlations between PC, FVIII and AT at different stages afte allogenic graft infusion.
Time points (d = transplantation day)
d –10 d—2 d + 10 d + 24 d + 38 d + 52 d + 90
PC vs FVIII:C R 0.58 0.38 0.64 0.64 0.82 0.76
p 0.001 0.037 < 0.001 < 0.001 < 0.001 < 0.001
PC vs AT R 0.49 0.62 0.62 0.75 0.81 0.64 0.69
p 0.007 0.01 0.01 0.01 0.01 0.01 0.01
R–Spearman’s rank correlation coefficient, p < 0.05
https://doi.org/10.1371/journal.pone.0190007.t001
Fig 2. Variability of APC-PCI between different time points during allogenic SCT. Activated protein C
complexed with its inhibitor (APC-PCI) was measured at 6 time points. Data are presented as median values
and error bars as the 25th and 75th percentiles; comparisons were with baseline values; d = transplantation/
graft infusion day; * = p < 0.05; ** = p < 0.001.
https://doi.org/10.1371/journal.pone.0190007.g002
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Fig 3. Natural anticoagulants and endothelial activation markers associated with aGVHD. Differences
between the group of acute GVHD (aGVHD+, N = 8) and without GVHD (aGVHD-, N = 22), are depicted for
(A) FVIII, (B) s-TM endothelial antigen, (C) protein C (PC) activity and (D) antithrombin. Data on panels (A)
and (B) are presented as median values with error bars as the 25th and 75th percentiles; and on panels (C)
and (D) as mean values and error bars as the standard errors; d = transplantation day; * = p < 0.05;
** = p < 0.01.
https://doi.org/10.1371/journal.pone.0190007.g003
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the present study, we have evaluated natural anticoagulants in the same blood samples. We
found that the activated PC and complexed with PCI responded immediately to the thrombin
challenge during conditioning therapy. Endothelial markers paralleled PC later following
engraftment. We also found that low PC activity during the conditioning therapy predicted
later development of acute GVHD.
The AT and PC activities were changing in parallel. This is somewhat surprising because
PC and TM engage different inhibitory mechanisms. It is likely that AT and PC are carried by
the same endothelial vesicles. It was shown previously that the TM-PC and the AT-heparan
sulphate complexes are shed by endothelium into circulation [24]. Circulatory microvesicles
play important role in interactions between inflammatory, immune and coagulation systems
[25], and in regulation of sepsis (24).
Our longitudinal monitoring of protein C system in SCT patients allowed discovering a
unique long-lasting balance between PC, APC and thrombin. Normally, acute thrombin gen-
eration causes rapid, a minute- scale rise of APC level [26]. The normal molar ratio of PC to
APC in human plasma is approximately 2000:1 [27], securing a large reserve for rapid APC
formation upon TM-dependent activation. Under prolonged thrombin formation and/or
inflammatory challenges maintenance of PC-APC function may be compromised. For exam-
ple, patients with sepsis develop PC deficiency caused by exhaustion and/or disturbed activa-
tion of PC precursor- zymogen in circulation [28]. Low or dysfunctional PC coincides with
shedding of endothelial TM and poor prognosis in critically ill patients [29].
Alteration in integrity of vasculature contributes to GVHD [14]. The endothelial damage
initiated by condition therapy perpetuates and manifests endothelial parameters alterations in
later time points.
The analysis of protein C system in groups with- and without GVHD indicates that defec-
tive APC generation in response to thrombin may predispose to GVHD suggesting causal
relationship between low PC during the conditioning therapy and later occurrence of GVHD.
This low PC during preconditioning in the GVHD may result from a higher level of endothe-
lial injury. We have also suggested a ratio F1+2/APC-PCI as a new parameter to monitor coag-
ulation-anticoagulation “dysregulated” responses over time during SCT.
Endothelial damage, mediated by proinflammatory cytokines, underlies the pathogenesis of
many complications after myeloablative allogeneic SCT [30]. Shedding of TM by damaged
endothelium is manifested by an increased level of circulating s-TM after engraftment. Indeed,
an earlier study found an association between GVHD and s-TM Ag [31]. Monitoring of s-TM
in our patients showed that s-TM became functional at later time points during SCT recovery.
Since the activation of PC by phospholipid-bound TM is much faster than by free TM [32],
the contribution of s-TM to activation of PC in SCT throughout our time points, may depend
on associating with microparticles in circulation. The increase of s-TM after engraftment was
paralleled by increase of FVIII: C, reflecting endothelial activation. Our data agree with previ-
ously observed increase of von Willebrand factor (a carrier of FVIII) after transplantation [33].
Interestingly, recombinant s-TM appeared successful in the treatment of capillary leakage syn-
drome, an early complication after allogeneic SCT [34].
Our TM findings are in line with a published data related to TM and GVHD. The higher
level of TM was observed in GVHD patients after umbilical cord blood transplantation [35]. A
study of temporal changes of TM in myeloablative recipients reported by Cutler et al. [36] con-
cluded that TM level higher than 100 ng/mL on the d+7 day predicted the occurrence of veno-
oclusive disease (VOD). In a study of bone marrow transplantation [37] an increase of TM
plasma levels at days 15 and 22 after conditioning therapy associated with clinical complica-
tions such as septicaemia, GVHD and VOD.
Allogeneic stem cell transplantation and natural anticoagulants
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The present study focused on temporal changes of the seven variables of endothelial activ-
ity, blood coagulation and its regulation, and their differences between the groups either devel-
oping GVHD or not. We recognize that possible confounders, such as preventive drugs, draft
source and donor type can contribute to our observations in our relatively small study.
In summary, our results revealed new interactive regulatory mechanisms activated in
response to allogenic SCT and development of GVHD. These interactions occurred despite a
limited number of patients with multiple confounding factors, such as different drugs, grafts,
donor types and infections. The time course of TM and PC activities suggests that PC-APC
system undergoes adaptation to vascular alterations and inflammation during conditioning,
engraftment and recovery. Therein, we propose that degree of PC activity during precondi-
tioning might be an indicator of future GVHD. Overall, monitoring of the coordination
between variables of endothelial activation, coagulation and natural anticoagulants may lead
to discoveries, which will alleviate complications of SCT.
Supporting information
S1 Table. Raw data. Raw data related to measurements of natural anticoagulants in plasma
of 30 SCT patients. The columns contain the following data: presence of acute GVHD
(1 = aGVHD+, 0 = aGVHD-), type of donor (1 = unrelated donor, 0 = siblings), type of graft
(1 = peripheral blood, 0 = bone marrow), protein C (PC) (7 time points), FVIII:C (7 time
points),antithrombin (AT) (8 time points), soluble thrombomodulin (s-TM) activity (Act) (6
time points), s-TM antigen (Ag) (6 time points), protein S (PS) (7 time points), activated PC
(APC) and protein C inhibitor complex (APC-PCI) (7 time points).
(ZIP)
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Hillarp, Ann-Kristin Öhlin, Liisa Volin, Riitta Lassila.
Project administration: Anne Pinomäki, Riitta Lassila.
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